Literature DB >> 11371663

Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.

P Roux-Lombard1, K Eberhardt, T Saxne, J M Dayer, F A Wollheim.   

Abstract

OBJECTIVE: To assess how serum concentrations of some cytokines, proteases and their inhibitors and cartilage oligomeric matrix protein (COMP) relate to the evolution of clinical disease and joint damage in early rheumatoid arthritis (RA).
METHODS: Annual assessment was performed in 24 RA patients subdivided into three groups according to disease severity as determined by the radiological progression rate. All patients were followed for 5 yr after inclusion. Functional status, Larsen's radiographic index in hands and feet (joint damage score, JDS) and C-reactive protein (CRP) were assessed annually and compared with interleukin (IL)-6, IL-10, the IL-1 receptor antagonist (IL-1Ra), promatrix metalloproteinase 3 (proMMP-3), tissue inhibitor of metalloproteinases 1 (TIMP-1) and COMP, which were determined by specific immunological tests.
RESULTS: The median JDS was initially between 4.5 and 7. During the study time the progression of JDS was 1 (median) for patients with slow progression, 33 for patients with intermediate progression and 62 for patients with rapid progression. Changes in CRP and proMMP-3 concentrations over time differed significantly between the groups, but no significant difference was observed for IL-1Ra, TIMP-1 or COMP. ProMMP-3 was closely related to CRP at each time point. IL-6 correlated significantly with CRP at the last four annual follow-up examinations. CRP and proMMP-3 correlated with JDS at the last two or three examinations and the combined levels of these markers over 5 yr correlated significantly with joint damage progression (Spearman rank correlation 0.73 and 0.74 respectively). IL-1Ra showed a weak negative correlation with JDS, and COMP tended to correlate with JDS only at the start. The initial proMMP-3 concentration was the only significant variable predicting rapidly developing joint damage, but the predictive value was low.
CONCLUSIONS: ProMMP-3 correlated closely at all time points with CRP, but gave little or no additional clinical information regarding inflammation or radiographic progression. IL-1Ra and TIMP-1 showed weaker, acute-phase-like variation, which may reflect pathogenic agonist/inhibitor imbalance in the evolution of RA. COMP, in contrast, did not reflect the inflammatory CRP-related component of the disease or the destructive aspect in this study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371663     DOI: 10.1093/rheumatology/40.5.544

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

Review 1.  Matrix metalloproteinase inhibitors in rheumatic diseases.

Authors:  D R Close
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Early stages of osteoarthritis: the search for sensitive predictors.

Authors:  F A Wollheim
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  The potential value of blood biomarkers of intervertebral disk metabolism in the follow-up of patients with sciatica.

Authors:  Federico Balagué; Margareta Nordin; Dominique Schafer; Ali Sheikhzadeh; Mary Ellen Lenz; Eugene M A Thonar
Journal:  Eur Spine J       Date:  2005-07-01       Impact factor: 3.134

4.  The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.

Authors:  Srinivasan Srirangan; Ernest H Choy
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

5.  Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future.

Authors:  Paula I Burgos; Maria I Danila; James M Kelley; Laura B Hughes; S Louis Bridges
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

6.  Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.

Authors:  G Morozzi; M Fabbroni; F Bellisai; S Cucini; A Simpatico; M Galeazzi
Journal:  Clin Rheumatol       Date:  2007-02-07       Impact factor: 2.980

7.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

Authors:  Norihiro Nishimoto; Jun Hashimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Norikazu Murata; Désirée van der Heijde; Tadamitsu Kishimoto
Journal:  Ann Rheum Dis       Date:  2007-05-07       Impact factor: 19.103

8.  Prognostic laboratory markers of joint damage in rheumatoid arthritis.

Authors:  E Lindqvist; K Eberhardt; K Bendtzen; D Heinegård; T Saxne
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

Review 9.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

10.  Review of tocilizumab in the treatment of rheumatoid arthritis.

Authors:  Yasuaki Okuda
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.